[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201701139YA - Abiraterone acetate formulation and methods of use - Google Patents

Abiraterone acetate formulation and methods of use

Info

Publication number
SG11201701139YA
SG11201701139YA SG11201701139YA SG11201701139YA SG11201701139YA SG 11201701139Y A SG11201701139Y A SG 11201701139YA SG 11201701139Y A SG11201701139Y A SG 11201701139YA SG 11201701139Y A SG11201701139Y A SG 11201701139YA SG 11201701139Y A SG11201701139Y A SG 11201701139YA
Authority
SG
Singapore
Prior art keywords
methods
abiraterone acetate
acetate formulation
formulation
abiraterone
Prior art date
Application number
SG11201701139YA
Inventor
Maura Murphy
Paul Nemeth
H William Bosch
Matthew Callahan
Satya Bhamidipati
Jason Coleman
Christopher Hill
Marck Norret
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201701139Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of SG11201701139YA publication Critical patent/SG11201701139YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
SG11201701139YA 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use SG11201701139YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
SG11201701139YA true SG11201701139YA (en) 2017-03-30

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701139YA SG11201701139YA (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Country Status (17)

Country Link
EP (1) EP3193857A4 (en)
JP (1) JP2017528457A (en)
KR (2) KR102491439B1 (en)
CN (1) CN106687112A (en)
AP (1) AP2017009804A0 (en)
AU (1) AU2015317466A1 (en)
BR (1) BR112017003219A2 (en)
CA (1) CA2958316A1 (en)
CO (1) CO2017002472A2 (en)
EA (1) EA201790650A1 (en)
IL (1) IL250270B (en)
MD (1) MD20170048A2 (en)
MX (1) MX2017003525A (en)
PH (1) PH12017500239A1 (en)
SG (1) SG11201701139YA (en)
TN (2) TN2018000318A1 (en)
WO (1) WO2016044701A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
KR20200021451A (en) * 2017-04-07 2020-02-28 엠에이에이 래보러토리스, 인코포레이티드 How to improve the solubility and bioavailability of therapeutic agents
WO2020151633A1 (en) * 2019-01-25 2020-07-30 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
DK3935068T3 (en) 2019-03-06 2023-12-04 Propella Therapeutics Inc ABIRATERON PRODUCT DRUGS
CN110742870B (en) * 2019-12-04 2021-04-20 武汉大学 Abiraterone acetate preparation and preparation method thereof
CN111110646A (en) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 Prescription and preparation method of low-specification abiraterone acetate oral preparation
CN113384542B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof
BR112022022534A2 (en) * 2020-05-08 2022-12-13 Janssen Pharmaceutica Nv PROSTATE CANCER TREATMENTS WITH ABIRATERONE ACETATE AND NIRAPARIB COMBINATIONS
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN117120034A (en) 2021-02-15 2023-11-24 普洛佩拉治疗公司 Abiraterone prodrugs
KR20240044329A (en) 2022-09-28 2024-04-04 한미약품 주식회사 Oral composite tablet comprising abiraterone acetate and prednisolone
KR20240145412A (en) 2023-03-27 2024-10-07 한미약품 주식회사 Pharmaceutical formulation comprising abiraterone acetate and prednisolone and method for preparing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201401705VA (en) * 2009-04-24 2014-08-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (en) 2012-07-27 2012-10-24 海南盛科生命科学研究院 Medicinal composition containing abiraterone acetate and preparation technology thereof
KR20160023641A (en) 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 Abiraterone acetate formulation

Also Published As

Publication number Publication date
MX2017003525A (en) 2017-06-21
TN2018000318A1 (en) 2020-01-16
EP3193857A4 (en) 2018-04-11
CA2958316A1 (en) 2016-03-24
BR112017003219A2 (en) 2017-11-28
TN2017000098A1 (en) 2018-10-19
CN106687112A (en) 2017-05-17
WO2016044701A1 (en) 2016-03-24
KR102617537B1 (en) 2023-12-22
AU2015317466A1 (en) 2017-02-23
PH12017500239A1 (en) 2017-07-03
IL250270B (en) 2021-02-28
AP2017009804A0 (en) 2017-03-31
KR20170070025A (en) 2017-06-21
JP2017528457A (en) 2017-09-28
CO2017002472A2 (en) 2017-07-11
EA201790650A1 (en) 2017-07-31
EP3193857A1 (en) 2017-07-26
MD20170048A2 (en) 2017-08-31
IL250270A0 (en) 2017-03-30
KR20230014878A (en) 2023-01-30
KR102491439B1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
HRP20210526T8 (en) Oxysterols and methods of use thereof
IL289976A (en) Oxysterols and methods of use thereof
IL250415B (en) Anti-pdl- antibodies and methods of use thereof
IL250270B (en) Abiraterone acetate formulation and methods of use
HK1255500A1 (en) Oxysterols and methods of use thereof
SG10202002593SA (en) Activated bifidobacteria and methods of use thereof
GB201421847D0 (en) Dispensers and methods of use thereof
EP3157528A4 (en) Oxysterols and methods of use thereof
GB201417048D0 (en) Occupancy-control device and methods of use
IL280082A (en) Neuroactive steroid solutions and their methods of use
EP3190886A4 (en) Compositions and methods of use thereof
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
HK1243404A1 (en) Tryptamide compositions and methods of use
IL246944A0 (en) Procedure for the preparation of abiraterone acetate and intermediates thereof
GB201408171D0 (en) Formulation and method of manufacture
GB2537518B (en) Settable compositions and methods of use
GB201509977D0 (en) Dispensers and methods of use thereof
AU2014905266A0 (en) Formulation and method of use
GB201408738D0 (en) Components and methods for formulation of components
AU2014905067A0 (en) Compositions and methods of use
AU2014902829A0 (en) Compositions and Methods of Use
AU2014904885A0 (en) Device and method of use
GB201416797D0 (en) Contianer and method of use thereof
GB201419844D0 (en) An aircraft and method of use thereof